Scientific Reports (Aug 2021)

Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

  • Sheng-Dean Luo,
  • Shao-Chun Wu,
  • Wei-Chih Chen,
  • Ching-Nung Wu,
  • Tai-Jan Chiu,
  • Yao-Hsu Yang,
  • Shau-Hsuan Li,
  • Fu-Min Fang,
  • Tai-Lin Huang,
  • Chang-Chun Hsiao,
  • Chang-Han Chen

DOI
https://doi.org/10.1038/s41598-021-96614-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.